Study: Transgender Mortality Rate Twice as High
Sept 8, 2021 1:34:20 GMT -5
Post by Shoshanna on Sept 8, 2021 1:34:20 GMT -5
Study: Transgender Mortality Rate Twice as High as Those Without Gender Dysphoria
DR. SUSAN BERRY
7 Sep 2021311
4:19
Analysis of data compiled from the Netherlands reveals transgender individuals have a significantly higher mortality rate when compared to people without gender dysphoria, an outcome that suggests a need to closely examine the effects of hormone treatments.
The Lancet Diabetes & Endocrinology journal published a report Thursday on the data that was compiled from medical records over five decades.
Researchers Martin den Heijer, Ph.D., of Amsterdam University Medical Centre (UMC) and colleagues found mortality risk among the transgender population did not decrease between 1972 and 2018.
“The findings of our large, nationwide study highlight a substantially increased mortality risk among transgender people that has persisted for decades,” den Heijer said in a statement reported by HCPLive.
He added the observational data analysis suggests cross-sex hormone treatments may not be as safe in the long term as has been accepted:
Gender-affirming hormone treatment is thought to be safe, and most causes of death in the cohort were not related to this. However, as there is insufficient evidence at present to determine their long-term safety, more research is needed to fully establish whether they in any way affect mortality risk for transgender people.
UMC operates a gender identity clinic, and, as the authors explain, data of transgender individuals who received hormone treatments between 1972 and 2018 were linked to Statistics Netherlands.
The study included the data of 4,568 adult transgender individuals – 2927 transgender women (biological men) and 1641 transgender men (biological women). The mean age of the patient population at the start of hormone treatments was 30 years for transgender women and 23 years for transgender men.
Continued at link
DR. SUSAN BERRY
7 Sep 2021311
4:19
Analysis of data compiled from the Netherlands reveals transgender individuals have a significantly higher mortality rate when compared to people without gender dysphoria, an outcome that suggests a need to closely examine the effects of hormone treatments.
The Lancet Diabetes & Endocrinology journal published a report Thursday on the data that was compiled from medical records over five decades.
Researchers Martin den Heijer, Ph.D., of Amsterdam University Medical Centre (UMC) and colleagues found mortality risk among the transgender population did not decrease between 1972 and 2018.
“The findings of our large, nationwide study highlight a substantially increased mortality risk among transgender people that has persisted for decades,” den Heijer said in a statement reported by HCPLive.
He added the observational data analysis suggests cross-sex hormone treatments may not be as safe in the long term as has been accepted:
Gender-affirming hormone treatment is thought to be safe, and most causes of death in the cohort were not related to this. However, as there is insufficient evidence at present to determine their long-term safety, more research is needed to fully establish whether they in any way affect mortality risk for transgender people.
UMC operates a gender identity clinic, and, as the authors explain, data of transgender individuals who received hormone treatments between 1972 and 2018 were linked to Statistics Netherlands.
The study included the data of 4,568 adult transgender individuals – 2927 transgender women (biological men) and 1641 transgender men (biological women). The mean age of the patient population at the start of hormone treatments was 30 years for transgender women and 23 years for transgender men.
Continued at link
